Qiming Corporate GP VI, Ltd. sold $5.7M of ALMR (indirect holdings)
Qiming Corporate GP VI, Ltd. sold 187,636 indirectly-held shares of Alamar Biosciences, Inc. (ALMR) at an average of $30.25 ($29.84–$33.31, $5.68M total) across 24 trades over 2026-10-30 to 2026-11-02. Filed jointly with Qiming Managing Directors Fund VI, L.P. (10% owner), Qiming Venture Partners VI, L.P. (10% owner), Qiming GP VIII, LLC (10% owner), Qiming Venture Partners VIII Investments, LLC (10% owner), Qiming GP VIII-HC, LLC (10% owner) and Qiming Venture Partners VIII-HC, L.P. (10% owner).
How this was made
The 30-second read
Why it matters
The disclosed sale reduces the insider's holding and may be interpreted as reduced confidence, potentially prompting short sellers.
Market read
Primary source filing; modest materiality due to small transaction size.
What to watch
Potential upcoming clinical data or financing needs not disclosed.
Background
SEC Form 4 filing discloses an insider transaction by a 10% owner of Alamar Biosciences, Inc.
Ticker impact
Form 4 shows Qiming Corporate GP VI sold ~187k shares of ALMR for $5.7M, reducing its stake to 1.67M shares.
likely downward pressure as the market prices the insider sell
A 10% owner sold shares worth $5.7M; such insider sales often lead to short-term price weakness.
Market effects
Minimal impact on the broader biotech sector; the sale is company‑specific.
No notable regional effect.
Limited to investors tracking ALMR.
Counterpoint
The sale could be a routine liquidity move, not a negative signal.
Key entities
- companyAlamar Biosciences, Inc.
Biotech firm whose shares were sold.
- insiderQiming Corporate GP VI, Ltd.
10% owner reporting the sale.



